A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: 10.1111/j.1751-7176.2010.00322.x.

Slides:

Advertisements

Similar presentations

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center.

Advertisements

Is it useful to control blood pressure faster in hypertensive patients? Based on: Gradman AH et al. Hypertension. 2013;61:

Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544) Randomisation Avoid ACE inhibitors/ beta-blockers (n = 390) Tight BP control (n =

JNC 8 Guidelines….

Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.

NHANES III Prevalence of Hypertension* According to BMI

N=1.831n=3.739n=3.374n=15.904n=13.297n=2.081 BP stratification according with 2003 ESH/ESC guidelines in Italian hypertensive patients included in population.

Rimoldi SF et al. J Clin Hypertens (Greenwich). 2015;17(3): Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive.

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

Epidemiology Prevalence Increase with age 25% of the white males vs. 17% in white females 44% of black males vs. 37% in black femals Indifference between.

Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.

William B. Kannel, MD, FACC Former Director, Framingham Heart Study

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,

AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.

New concept – no traditional combination LODOZ contains Bisoprolol and Hydrochlorothiazide in subtherapeutic dosages: - Bisoprolol 2.5 mg (= half / quarter.

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.

1 Improving Chronic Care Management David M. Cutler Presented at Alliance for Health Reform Novartis/NIHCM Briefing March 28, 2008.

Comparison of Blood Pressure Lowering with Hydrochlorothiazide and Chlorthalidone Kurt A. Wargo, Pharm.D., BCPS, Thomas M. English, Ph.D., Anna J. Aaron,

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,

Control and monitoring for 6 years of patients with Hypertension in the community at the National University of Santiago del Estero, Argentina 3rd International.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.

Hypertension and Obesity among a Religious Group in the Akwapim North District of Ghana, 2012 J. K.L Opare 1, 2, C. Ohuabunwo 3, E. Afari 1, F. Wurapa.

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.

HvC Comparative Effectiveness Project Groups 5 and 6

Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) PI: Jan Hirsch, RPh, PhD Carol M. Mangione, MD, MSPH Barbara A. Levey.

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

Efficacy and Comparability of Thiazide-type Diuretics

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

1 Mosby items and derived items © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier, Inc. Nursing Management: Hypertension Chapter 33.

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

2007 Hypertension as a Public Health Risk January, 2007.

Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,

Saleem Jessani 1, Rasool Bux 1 and Tazeen H. Jafar 1,2. 1 Aga Khan University, Karachi, Pakistan 2 Duke-NUS Graduate Medical School, Singapore Socio-demographic.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Hypertension November 2016

From ESH 2016 | POS 3C: Chiara Lorenzi, MD

Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI Clinical Therapeutics

From ESH 2016 | POS 7D: Jan Rosa, MD

Renal Denervation Next Steps

Vanguard Phase Results for the Blood Pressure Component

Flowchart of participants

Copyright © 2007 American Medical Association. All rights reserved.

Circ Cardiovasc Qual Outcomes

Improving Chronic Care Management

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

End point Net change with soy supplements vs control (95% CI) p

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Hypertension November 2016

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Volume 73, Issue 8, Pages (April 2008)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

End point Valsartan Valsartan+HCTZ p

Mean Pulmonary Artery Pressure Change Post-Thrombectomy Average pre-procedural mean pulmonary artery pressure (mPAP) in patients with pulmonary hypertension.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.

Presentation transcript:

A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x Problematic: Scarce data on BP treatment, BP control and drug utilization on global scale Goal: Resolve the lack of information to gain further insight into national and regional BP control and antihypertensive pharmacotherapy prescribed in practice by analyzing the data of i-SEARCH (International survey)

i-SEARCH method 26 countries across the world (n=18 652)

i-SEARCH method Baseline characteristics: Treated patients:n= Age (years): 63.0 ± 11.4 Sex (male): 52.2% Type 2 diabetes: 24.3% SBP (mm Hg): ± 19.8 DBP (mm Hg): 86.7 ± 11.6

The majority of hypertensive patients are uncontrolled BP control (%) Uncontrolled Patients

1 hypertensive patient out of 3 is treated by 3 drugs

Similar use of drug regardless of the region of the world

BP reading were on average too high and not tailored toward an increased risk Potential for an improvement of BP control in daily practice This would result in considerable reductions of morbidity Conclusion